

**Supplementary Table S1.** Reason for discontinuation of secukinumab treatment.

	n (%)
Patients who discontinued	64 (36%)
Primary inefficacy	16 (25%)
Secondary inefficacy	37 (57.8%)
Adverse events	11 (17.2%)

**Supplementary Table S2.** Characteristics of patients who discontinued secukinumab treatment.

	Median (IQR 25–75)
Weight (kg)	82.5 (72–91)
Height (cm)	169.0 (160.0–175.0)
BMI (kg/m <sup>2</sup> )	28.0 (25.8–31.1)
Age at diagnosis (years)	53.5 (47–60)
Disease duration from diagnosis to secukinumab prescription (years)	4 (1–8)
Therapy duration at discontinuation or last follow-up (months)	11 (5–23.5)